Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the head and neck~  * All primary sites, including oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and paranasal sinus~* Recurrent, unresectable, and/or metastatic disease~* At least 1 measurable lesion~  * At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan~* Lesions accessible for biopsy~* Tumor specimen available for evaluation of epidermal growth factor receptor (EGFR) expression~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy:~* More than 12 weeks~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.25 times upper limit of normal (ULN)~* AST and ALT no greater than 2.5 times ULN~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Gastrointestinal:~* No gastrointestinal tract disease resulting in malabsorption~* No requirement for IV alimentation~* No active peptic ulcer disease~* Inability to swallow tablets or silicon-based G-tubes allowed~Ophthalmic:~* No abnormalities of the cornea based on history (e.g., dry eye syndrome or Sjogren's syndrome)~* No congenital abnormality (e.g., Fuch's dystrophy)~* No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)~* No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except carcinoma in situ of the cervix, nonmelanoma skin cancer, or second primary squamous cell cancer originating from the head and neck~* No grade 2 or greater residual ototoxicity or neuropathy from prior platinum-based therapy~* No significant traumatic injury within the past 21 days~* No other concurrent uncontrolled illness~* No ongoing or active infection~* No psychiatric illness or social situation that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for recurrent or metastatic disease~* Prior platinum-based chemotherapy with radiotherapy or platinum-based induction chemotherapy allowed~* At least 6 months since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Chemotherapy~* At least 4 weeks since prior radiotherapy (except low-dose, limited-fraction palliative non-myelosuppressive radiotherapy \[e.g., involving less than 20% of functioning bone marrow using 800 cGy in 1 fraction or 2,000 cGy in 5 fractions\]) and recovered~* No prior radiotherapy to target lesion unless there is evidence of disease progression~Surgery:~* See Disease Characteristics~* At least 21 days since prior major surgery~* No prior surgical procedure affecting gastrointestinal absorption~Other:~* No prior EGFR-targeting therapies~* No prior investigational agents for recurrent or metastatic disease~* No concurrent combination anti-retroviral therapy for HIV infection~* No other concurrent investigational agents~* No other concurrent anticancer treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- OSI-774 and cisplatin (Type: EXPERIMENTAL): HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).